Headlines about PAVmed (NASDAQ:PAVM) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PAVmed earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 48.965549835502 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several analysts have recently weighed in on the stock. Dawson James reaffirmed a “buy” rating and issued a $10.10 target price on shares of PAVmed in a report on Tuesday, September 5th. ValuEngine raised shares of PAVmed from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.

Shares of PAVmed (NASDAQ PAVM) traded down $0.11 during trading hours on Wednesday, hitting $3.90. 4,600 shares of the stock traded hands, compared to its average volume of 8,710. PAVmed has a 1-year low of $2.54 and a 1-year high of $10.72.

PAVmed (NASDAQ:PAVM) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. sell-side analysts expect that PAVmed will post -0.7 EPS for the current year.

In related news, CFO Dennis M. Mcgrath acquired 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average price of $4.21 per share, with a total value of $25,260.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have purchased 13,950 shares of company stock worth $57,653. 79.30% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect PAVmed (PAVM) Share Price” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/11/15/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-pavmed-pavm-share-price.html.

About PAVmed

PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

Insider Buying and Selling by Quarter for PAVmed (NASDAQ:PAVM)

Receive News & Stock Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related stocks with our FREE daily email newsletter.